Estimating the Impact of Plasma HIV-1 RNA Reductions on Heterosexual HIV-1 Transmission Risk by Lingappa, Jairam R. et al.
 
Estimating the Impact of Plasma HIV-1 RNA Reductions on
Heterosexual HIV-1 Transmission Risk
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Lingappa, Jairam R., James P. Hughes, Richard S. Wang, Jared M.
Baeten, Connie Celum, Glenda E. Gray, Wendy S. Stevens, et al.
2010. Estimating the Impact of Plasma HIV-1 RNA Reductions on
Heterosexual HIV-1 Transmission Risk. PLoS ONE 5(9): e12598.
Published Version doi:10.1371/journal.pone.0012598
Accessed February 19, 2015 8:16:48 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10482816
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAEstimating the Impact of Plasma HIV-1 RNA Reductions
on Heterosexual HIV-1 Transmission Risk
Jairam R. Lingappa
1,2,3*, James P. Hughes
4, Richard S. Wang
1, Jared M. Baeten
1,2,5, Connie Celum
1,2,5,
Glenda E. Gray
6, Wendy S. Stevens
7,8, Deborah Donnell
9,10, Mary S. Campbell
1,2, Carey Farquhar
1,2,5,M .
Essex
11, James I. Mullins
1,2,12,13, Robert W. Coombs
1,2,13, Helen Rees
14, Lawrence Corey
1,2,10,13, Anna
Wald
1,2,5,10,13, for the Partners in Prevention HSV/HIV Transmission Study Team
"
1Department of Global Health, University of Washington, Seattle, Washington, United States of America, 2Department of Medicine, University of Washington, Seattle,
Washington, United States of America, 3Department of Pediatrics, University of Washington, Seattle, Washington, United States of America, 4Department of Biostatistics,
University of Washington, Seattle, Washington, United States of America, 5Department of Epidemiology, University of Washington, Seattle, Washington, United States of
America, 6Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, Republic of South Africa, 7Department of Molecular Medicine and Haematology,
University of the Witwatersrand, Johannesburg, Republic of South Africa, 8National Health Laboratory Service, University of the Witwatersrand, Johannesburg, Republic of
South Africa, 9Statistical Center for HIV/AIDS, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America, 10Vaccine and Infectious Disease
Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America, 11Department of Immunology and Infectious Diseases, School of
Public Health, Harvard University, Boston, Massachusetts, United States of America, 12Department of Microbiology, University of Washington, Seattle, Washington,
United States of America, 13Department of Laboratory Medicine, University of Washington, Seattle, Washington, United States of America, 14Reproductive Health and
HIV Research Unit, University of the Witwatersrand, Johannesburg, Republic of South Africa
Abstract
Background: The risk of sexual transmission of HIV-1 is strongly associated with the level of HIV-1 RNA in plasma making
reduction in HIV-1 plasma levels an important target for HIV-1 prevention interventions. A quantitative understanding of the
relationship of plasma HIV-1 RNA and HIV-1 transmission risk could help predict the impact of candidate HIV-1 prevention
interventions that operate by reducing plasma HIV-1 levels, such as antiretroviral therapy (ART), therapeutic vaccines, and
other non-ART interventions.
Methodology/Principal Findings: We use prospective data collected from 2004 to 2008 in East and Southern African
HIV-1 serodiscordant couples to model the relationship of plasma HIV-1 RNA levels and heterosexual transmission risk
with confirmation of HIV-1 transmission events by HIV-1 sequencing. The model is based on follow-up of 3381 HIV-1
serodiscordant couples over 5017 person-years encompassing 108 genetically-linked HIV-1 transmission events. HIV-1
transmission risk was 2.27 per 100 person-years with a log-linear relationship to log10 plasma HIV-1 RNA. The model
predicts that a decrease in average plasma HIV-1 RNA of 0.74 log10 copies/mL (95% CI 0.60 to 0.97) reduces
heterosexual transmission risk by 50%, regardless of the average starting plasma HIV-1 level in the population and
independent of other HIV-1-related population characteristics. In a simulated population with a similar plasma HIV-1
RNA distribution the model estimates that 90% of overall HIV - 1i n f e c t i o n sa v e r t e db ya0 . 7 4c o p i e s / m Lr e d u c t i o ni n
plasma HIV-1 RNA could be achieved by targeting this reduction to the 58% of the cohort with plasma HIV-1 levels $4
log10 copies/mL.
Conclusions/Significance: This log-linear model of plasma HIV-1 levels and risk of sexual HIV-1 transmission may help
estimate the impact on HIV-1 transmission and infections averted from candidate interventions that reduce plasma HIV-1
RNA levels.
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The risk of sexual transmission of HIV-1 correlates strongly
with plasma HIV-1 level.[1,2] This association has motivated
proposed interventions (such as use of antiretroviral therapy
(ART),[3,4] therapeutic HIV-1 vaccines,[5] and treatment for co-
infections[6–8] that reduce HIV-1 infectiousness by reducing
levels of plasma HIV-1 RNA. For example, epidemiologic studies
have found that reactivation of herpes simplex virus type 2 (HSV-
2) is associated with increased plasma and genital HIV-1
concentrations, and short-term clinical trials have demonstrated
that HSV-2 suppressive therapy (using acyclovir or valacyclovir)
significantly reduces plasma HIV-1 levels.[9–13] Based on these
findings, we conducted the Partners in Prevention HSV/HIV
Transmission Study to determine whether HSV-2 suppression in
an HIV-1/HSV-2 dually infected person reduced HIV-1 trans-
mission to the seronegative partner among African HIV-1
serodiscordant heterosexual couples (one partner HIV-1 infected
and the other uninfected). The primary analysis of this trial found
that, despite a 73% reduction in genital ulcer disease due to HSV-
2 and a 0.25 log10 reduction in plasma HIV-1 RNA levels
compared to the placebo arm, HSV-2 suppression with acyclovir
did not prevent HIV-1 transmission (hazard ratio 0.92, 95% CI
(0.60–1.41), p=0.70).[14] Although acyclovir reduced plasma
HIV-1 RNA levels by a similar magnitude as previous controlled
trials,[9–13] the effect was not sufficient to significantly reduce
HIV-1 transmission risk.
This finding raises the question of what reduction in plasma
HIV-1 levels would be required to reduce HIV-1 heterosexual
transmission risk. Detailed characterization of the relationship of
plasma HIV-1 RNA to HIV-1 infectiousness could help evaluate
the impact of proposed HIV-1 prevention interventions that
operate by reducing plasma HIV-1 RNA. We used the
prospectively collected data from this clinical trial to model the
relationship between plasma HIV-1 RNA in HIV-1 infected
partners and HIV-1 transmission risk in this population.
Methods
The clinical trial study design, including participant screening,
enrollment, follow-up, and laboratory methods, has been de-
scribed in detail elsewhere.[14] Briefly, stable heterosexual HIV-1
serodiscordant couples were recruited in 14 sites in East and
southern Africa. The HIV-1 infected partner, dually-infected with
HSV-2 and with a CD4 count $250 cells/mm3, was randomized
to HSV-2 suppression (acyclovir 400 mg orally twice daily) or
placebo, with study drug provided at monthly visits. HIV-1
serostatus in the initially HIV-1 uninfected partner was assessed
quarterly for up to 24 months by HIV-1 rapid assay, with HIV-1
seroconversions confirmed by ELISA and Western blot. HIV-1
transmission events were classified as ‘‘linked’’ (i.e., transmission
from an HIV-1 infected individual to his/her enrolled partner) by
comparing HIV-1 env and/or gag sequences of viruses from plasma
of the HIV-1 seroconverters and the HIV-1 infected partner with
whom they enrolled in the study.[14,15] End of study central
laboratory testing demonstrated that 27 of the 3408 couples did
not meet the HIV-1 (n=3) or HSV-2 (n=24) serologic eligibility
criteria leaving data from 3381 couples for this analysis. The HIV-
1 transmission endpoint for this analysis was genetically-linked
HIV-1 seroconversion including 17 linked seroconversions iden-
tified at the first quarterly study visit and retrospectively found to
be HIV-1 RNA RT-PCR positive at enrollment (and therefore not
included in the previously reported primary study analysis[14]).
Plasma HIV-1 RNA measurements (COBAS AmpliPrep/
COBAS TaqMan HIV-1 RNA assay, version 1.0, Roche
Diagnostics, Indianapolis, IN with a limit of quantification of
240 copies/mL) were performed at the University of Washington
on acid-citrate dextrose plasma collected from the HIV-1 infected
partner at the 0, 3, 6, and 12-month visits and at the final study
visit. Since plasma RNA levels from HIV-1 infected individuals in
this population were highly correlated over time (intraclass
correlation =0.69), visits without measured plasma HIV-1 RNA
level, but where HIV-1 seroconversion in the partner was
evaluated, were assigned the last measured plasma HIV-1 RNA
level carried forward. Undetectable plasma HIV-1 RNA levels
were included if the participant was known to be taking ART or if
plasma HIV-1 RNA was undetectable at a previous or subsequent
visit, thereby reducing the likelihood that the undetectable value
was a laboratory error. When included in this analysis,
undetectable RNA levels were set equal to half the limit of
quantification (120 copies/mL). For all seroconverters, plasma
HIV-1 RNA was evaluated at the visit prior to HIV-1
seroconversion.
Data from both randomization arms of this clinical trial were
used to model the relationship between plasma HIV-1 RNA level
and risk of linked HIV-1 seroconversion. The (natural) log of HIV-
1 transmission risk was modeled as a linear function of log10
plasma HIV-1 RNA using a Cox model with time-varying plasma
HIV-1 RNA level. A more flexible model for log10 plasma HIV-1
RNA that used a natural cubic spline with 4 knots was also
evaluated, and based on the results (see below) a linear model was
selected for subsequent analysis. Since risk of transmission is
commonly depicted on the non-log scale, this format was used to
graph this relationship.
Since 36 linked transmission events had plasma HIV-1
measured at a visit prior to documented seroconversion, we used
a sensitivity analysis to evaluate the use of the first positive HIV-1
test by either serology or RT-PCR as the endpoint in the Cox
model. We evaluated the following co-factors for HIV-1
transmission in this cohort for interaction with or confounding
of the relationship between plasma HIV-1 RNA level and HIV-1
transmission: baseline HSV-2 serology in the initially HIV-1
uninfected partner, male circumcision in HIV-1 infected and
HIV-1 uninfected partners, and gender. We also assessed
unprotected sex reported by the initially HIV-1 uninfected partner
a time-dependent factor measured every three months.
We developed a predictive tool to estimate the overall reduction
in HIV-1 transmissions for a given reduction in plasma HIV-1
RNA concentrations and, when applied to a hypothetical
population, to estimate the impact of such reductions in plasma
HIV-1 RNA on HIV-1 infections averted. We assume that the
HIV-1 incidence rate and plasma viral RNA distribution in the
hypothetical population is stable. To illustrate the use of this tool, a
fixed plasma HIV-1 RNA reduction was applied to two HIV-1
infected populations defined by the groups of the 4 highest versus
10 lowest HIV-1 incidence study sites. We then calculated the
number of HIV-1 infections averted over one year as the
difference between the expected HIV-1 infections in a population
of 100,000 seronegative persons exposed to HIV-1 infected
partners with the indicated population distribution of plasma
HIV-1 RNA.
The clinical trial protocol, including use of clinical trial data for
studies of determinants of HIV-1 transmission, and informed consent
documents were reviewed and approved by human subjects research
committees at the University of Washington and all local study site and
affiliated institutions. All clinical trial participants provided written
informed consent for participating in this research. The trial is registered
through ClinicalTrials.gov as NCT00194519 [http://clinicaltrials.gov/
ct2/show/NCT00194519?term=NCT00194519&rank=1].
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Among the 3381 couples included in this analysis, the HIV-1
infected partner was female in 2284 and male in 1097 couples.
The median CD4 count was 462 cells/mm3 (Table 1). A total of
5017 persons-years of follow-up were accumulated, of which 4756
(94.7%) had plasma HIV-1 RNA data available. During this
follow-up, we observed 108 linked HIV-1 transmissions (incidence
2.27 per 100 person-years).
Model characteristics
We fitted a log-linear relationship between log10 plasma HIV-1
RNA and HIV-1 transmission (Figure 1; p,0.0001). The model
generally fitted closely with measured incidence. At the highest
plasma virus levels (6–7 log10 copies/mL) both observed linked
HIV-1 transmissions (n=3) and observed follow-up (43 person-
years) were low, and the observed risk was flatter than the
predicted risk curve; however, a more flexible cubic spline model
did not significantly improve the fit in this range (p=0.21).
During the 938 person-years of follow-up associated with an
HIV-1 infected partner having low plasma HIV-1 RNA (2 to 3
log10 copies/mL), three HIV-1 transmissions were identified. The
maximum plasma HIV-1 RNA level measured at any point during
study follow-up for these three HIV-1 transmitting partners were
3.19, 3.95 and 4.71 log10 copies/mL.
The model predicts that, given the population distribution of
HIV-1 plasma RNA in this study, at plasma HIV-1 levels between
5–6 log10 copies/mL the risk of HIV-1 transmission is 2.6-fold
greater than at 4–5 log10 copies/mL, 6.5-fold greater than at 3–4
log10 copies/mL and 16.6-fold greater than at 2–3 log10 copies/
mL. Since these data fit a log-linear relationship, each one-log
increase in plasma RNA results in a 2.49-fold increased risk of
transmission. More specifically, reductions in plasma HIV-1 of 0.5,
0.74 and 1.48 log10 copies/mL applied to any plasma HIV-1 level
will result in 37%, 50% and 75% reductions in HIV-1
transmission risk, respectively (Table 2). In a sensitivity analysis
using time to first indication of HIV-1 infection (by earliest of
serology or RT-PCR) instead of time to HIV-1 seroconversion, the
plasma HIV-1 reduction required to decrease transmission risk by
50% was not meaningfully changed (0.82 versus 0.74 log10 copies/
mL).
We assessed whether the HIV-1 transmission risk versus plasma
RNA relationship differed based on HIV-1 incidence rates. We
applied the model to the subset of data from study sites with the
highest HIV-1 transmission rate (average 5.8 per 100 person-
years) versus study sites with lower HIV-1 incidence (average 1.8
per 100 person-years) and found no meaningful difference in the
log hazard ratio of transmission per log change in plasma HIV-1
level. Furthermore, factors known to affect HIV-1 transmission
(history of any unprotected sex, gender, HSV-2 seropositivity,
male circumcision of the HIV-1 uninfected partner) did not
significantly interact with or have a confounding effect on the
relationship between plasma HIV-1 RNA and risk of transmission.
Thus, changes in these characteristics in a population will not
significantly affect the impact of changes in plasma HIV-1 RNA
level on HIV-1 infections averted making this model broadly
applicable for this purpose.
Population-specific impact of plasma HIV-1 reductions on
HIV-1 infections averted
Our log-linear model predicts that the proportional decrease in
HIV-1 transmission risk associated with a given reduction in log10
plasma HIV-1 RNA is independent of the baseline plasma HIV-1
level. However, the absolute reduction in transmission risk
associated with a given reduction in plasma HIV-1 RNA will, of
course, be greater at higher plasma HIV-1 levels. Thus, the
number of HIV-1 infections averted by a reduction in plasma
HIV-1 will tend to be greater at higher plasma virus levels. To
illustrate this, we calculated the impact of a 0.74 log10 reduction in
plasma HIV-1 RNA applied to a population with the plasma HIV-
1 distribution of the high HIV-1 incidence versus the low-
incidence subset of clinical trial sites. This plasma HIV-1 RNA
reduction would translate to 2903 HIV-1 infections averted per
100,000 HIV-1 uninfected persons in the high-incidence popula-
tion compared to 902 per 100,000 in the low-incidence population
(constituting 50% of the new HIV-1 infections expected from each
of these populations, respectively) (Table 3).
Given the increased risk of transmission at higher levels of
plasma HIV-1 RNA, we estimated the potential impact on HIV-1
infections averted in the high incidence population if HIV-1
infected individuals were targeted with a reduction in plasma
HIV-1 levels based on their baseline plasma HIV-1 level. We
found that an intervention that reduced plasma HIV-1 by 0.74
log10 delivered to the 16.5% of individuals with plasma HIV-1
RNA between 5–6 log10 copies/mL in the high incidence
population would avert 1186 HIV-1 infections, compared to
1136 infections averted for the same plasma HIV-1 RNA
reduction applied to the 40.3% of persons in that population with
plasma HIV-1 RNA between 4–5 log10 copies/mL. Overall, in
this example, 88% of the total HIV-1 infections averted were
derived from the 58% of the population with plasma HIV-1 RNA
levels $4 log10 copies/mL. We have included in Table S1 an
application of this model that calculates HIV-1 transmission risk
and HIV-1 infections averted from data input by a user for the
plasma HIV-1 distribution and HIV-1 transmission incidence in
their selected study population.
Discussion
The Partners in Prevention HSV/HIV Transmission Study
provides the largest and most detailed database to date for
modeling the relationship of plasma HIV-1 RNA and risk of
heterosexual HIV-1 transmission, allowing us to model a predicted
impact of a reduction in plasma HIV-1 RNA on HIV-1
infectiousness. Our model assumes a linear relationship between
the logarithm of the risk of HIV-1 transmission and the logarithm
of plasma HIV-1 RNA; this assumption is validated by the
observed data particularly in the range of 3 to 6 log10 plasma
RNA. Thus, plasma HIV-1 RNA reductions of 0.5 log10 and 0.74
Table 1. Demographic characteristics of the study population
(N=3381).
Baseline Characteristic Number (%) or Median (IQR)
HIV-1 infected partner
Women 2284 (68%)
Median CD4 count (cells/mm
3) 462 (347–631)
HIV-1 uninfected partner
HSV-2 seropositive 2294 (68%)
Couple characteristics
Median number of sex acts in the
month prior to enrollment
4 (2–8)
Couples reporting unprotected sex
acts in the month prior to enrollment
1252 (37%)
doi:10.1371/journal.pone.0012598.t001
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the risk of HIV-1 transmission, respectively, regardless of the
baseline level of plasma HIV-1 RNA. Our findings are in close
agreement with those from a HIV-1 serodiscordant couples cohort
in Rakai, Uganda for which 0.5 and 0.74 log10 plasma HIV-1
RNA reductions were associated with 36% and 48% reductions in
HIV-1 transmission, respectively (reference (2); and personal
communication, Dr. Laith Abu-Raddad, Weill Cornell Medical
College, Qatar). However, it should be noted that viral sequence-
based linkage confirmation performed in our study cohort was not
performed in the Rakai study. Linkage confirmation was
performed in a prior study of Zambian HIV-1 serodiscordant
couples [1], but the specific measures of the relationship of plasma
HIV-1 and transmission risk discussed here have not been
reported for that cohort. Our findings are also similar to other
recent studies reporting reductions in HIV-1 transmission risk of
26%[16] and 40%[17] in association with a 0.5 log10 copies/mL
plasma HIV-1 RNA decrease. In addition to incorporating genetic
linkage of transmissions, our model is based on a larger cohort of
HIV-1 serodiscordant couples, with longer duration of follow-up,
than previous studies.
Epidemiologic co-factors for HIV-1 transmission (gender, HSV-
2 infection in the HIV-1 uninfected partner, male circumcision in
the HIV-1 uninfected partner and history of any unprotected sex)
did not interact with or confound the relationship of plasma HIV-
1 RNA levels to HIV-1 transmission risk. Since, based on study
eligibility criteria, all HIV-1 infected partners in this study cohort
were dually infected with HSV-2, we could not assess HSV-2
infection in the HIV-1 infected partner for interaction with the
relationship of HIV-1 plasma level and HIV-1 transmission.
Figure 1. The left y-axis is scaled so that a RR of 1 corresponds to the observed overall risk of transmission in the cohort (2.27% per
person-year)at the median (log) viral load. Themodel assumes a linearrelationship between log risk of HIV-1 transmissionandlog10 plasma HIV-1
RNA level with the solid line as the model-predicted risk of transmission and dashed lines are 95% point-wise confidence intervals (p,0.0001). The
numbers on the x-axis for the graph (plasma HIV-1 RNA) also indicate the range of plasma HIV-1 RNA values for each column of the table. The observed
data (number of HIV-1 transmission events, person-years of follow-up, calculated HIV-1 incidence and 95% confidence interval [CI]) and model data
(study population distribution of plasma HIV-1 RNA levels and proportion of transmissions) by level of plasma HIV-1 RNA are provided below the graph.
The 0.5% of the population with plasma HIV-1 RNA level ,2 log10 copies/ml and no observed transmissions are not included in this graph.
doi:10.1371/journal.pone.0012598.g001
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from this cohort compared to that derived from the Rakai cohort,
where the prevalence of HSV-2 antibody among HIV-1 infected
persons was lower (67%),[18] it is unlikely that HSV-2 infection
strongly interacts with this relationship. Therefore, we infer that
our model is both accurate and generally applicable to populations
with varied characteristics, particularly within the 2 to 6 log10
copies/mL range of plasma HIV-1 levels where this model has
greatest power.
Our data suggest that HIV-1 transmission risk increases
substantially with no evidence of biological saturation through a
range of plasma HIV-1 levels from 3 to 6 log10 copies/mL. In the
range of 6–7 log10 copies/mL we had a small number of events
(n=3) with few person-years of follow-up (n=43), so we cannot be
certain that the log-linear relationship holds at such high levels of
plasma HIV-1 RNA. Increased power to ascertain HIV-1
transmission risk in this high plasma HIV-1 stratum would
necessitate targeting HIV-1 serodiscordant couples with one
acutely infected and one HIV-1 uninfected partner, who are
difficult to identify. At the low end of the plasma HIV-1 RNA
spectrum (HIV-1 infected partners with plasma HIV-1 levels ,3
log10 copies/mL), we only observed three HIV-1 transmission
events over 968 person-years of follow-up. Given the small
number of events, it is possible that, in some cases, HIV-1 levels
immediately prior to HIV-1 transmission were transiently higher
than those documented at their scheduled visits. More generally,
since plasma HIV-1 levels were measured at 0, 3, 6, 12 months
and at study exit, and not at every quarterly visit, our estimate of
the relationship between HIV-1 transmission risk and HIV-1
plasma viral load may be somewhat attenuated. However, given
the high correlation of plasma HIV-1 RNA levels over time in our
dataset, our model is likely robust.
Antiretroviral therapy is currently the only therapeutic inter-
vention that consistently reduces plasma HIV-1 RNA by more
than 0.7 log copies/mL.[19,20] A recent analysis of our cohort
documented that ART use reduced risk of HIV-1 transmission by
92% (p=0.004) and an ongoing randomized trial will assess the
long-term effect of ART on HIV-1 transmission[21]. However,
current resources constrain many countries from providing ART
to all HIV-1 infected persons meeting current international
guidelines for treatment, and recent proposals[4] to perform
HIV-1 testing more broadly (‘‘test and treat’’) will accentuate this
challenge.
This model demonstrates that a 0.74 log10 copies/mL reduction
in HIV-1 plasma RNA reduces HIV-1 transmission by 50%, and
that 90% of these infections averted could be achieved by targeting
the plasma HIV-1 RNA reduction to a subset of the population
with plasma HIV-1 RNA levels $4 log10 copies/mL (less than
60% of HIV-1 infected persons, across a range of scenarios). While
ART for HIV-1 prevention may be made more cost-effective by
targeting persons with plasma HIV-1 RNA $4 log10 copies/mL,
given the current high cost and limited availability of plasma HIV-
1 RNA monitoring, significant advances in this technology would
be required before this approach could be implemented in
‘treatment for prevention’ algorithms[22] in resource-limited
settings. In the absence of a low-cost HIV-1 RNA assay, the
model and tool we have developed could be used to inform public
health resource allocation or to prioritize populations considered
for HIV-1 prevention clinical trials.
This model does not explicitly include the impact of stage of
HIV-1 infection on HIV-1 transmission potential. Given the long
Table 3. Impact of plasma HIV-1 RNA reduction on HIV-1 incidence and infections averted in high versus low incidence cohorts.
Cohort Characteristics
Plasma HIV-1 RNA
reduction (log10
copies/mL) Plasma HIV-1 RNA Level
#2
.2t o
3,3
.3
to 4
.4t o
5,5
.5
to 6
.6
to 7 Total
High incidence population (HIV-1 incidence - 5.8%/year)
1
Population distribution of plasma HIV-1 RNA (%) n/a 0.1 17 24.8 40.3 16.5 1.3 100
Percentage of HIV-1 transmissions (%) n/a ,0.01 3 9 39 41 8 1.00
# HIV-1 Infections averted (/year)
2 0.74 0 73 274 1136 1186 234 2903
Low incidence population (HIV-1 incidence - 1.8%/year)
1
Population distribution of plasma HIV-1 RNA (%) n/a 0.2 20.2 29.1 35.0 14.7 0.8 100
Percentage of HIV-1 transmissions (%) n/a ,0.01 3 12 38 41 6 1.00
# HIV-1 Infections averted (/year)
2 0.74 0 30 112 343 367 50 902
1High and low incidence populations include the subset of clinical trial sites with the highest and lowest HIV-1 incidence, respectively.
2The log-linear model is used to estimate HIV-1 infections averted per year as the difference in HIV-1 infections that would occur in that plasma RNA stratum if the
plasma HIV-1 RNA reduction is applied to a population of 100,000 HIV-1 uninfected persons compared to the number of HIV-1 infections expected in that population in
the absence of the plasma HIV-1 RNA reduction. The total number of new HIV-1 infections expected per year in these hypothetical examples are 5800 and 1800 for the
high and low incidence populations, respectively.
doi:10.1371/journal.pone.0012598.t003
Table 2. Plasma HIV-1 RNA reductions (and 95% Confidence
Intervals [CI]) predicted to result in selected levels of HIV-1
transmission risk reduction.
HIV-1 transmission
risk reduction
Plasma HIV-1 RNA reduction
(log10 copies/mL)
95% CI (log10
copies/mL)
25% 0.31 0.25–0.40
33% 0.43 0.34–0.56
37% 0.50 0.40–0.65
50% 0.74 0.60–0.97
67% 1.18 0.95–1.56
75% 1.48 1.19–1.95
doi:10.1371/journal.pone.0012598.t002
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infection can remain infectious, their overall contribution to HIV-
1 transmission may be higher than individuals at early and
advanced HIV-1 disease stages associated with higher plasma
HIV-1 RNA levels.[23] However, the plasma HIV-1 RNA levels
contributing to most HIV-1 infections in our study population (i.e.,
$4 log10 copies/mL) encompasses the median plasma HIV-1 level
of clinically latent infections potentially mitigating the impact of
explicit inclusion of stage of HIV-1 infection in the model.[24]
This model also does not include additional behavioral factors, or
viral and host factors that also contribute to HIV-1 infectiousness.
However, by modeling the relationship of plasma HIV-1 RNA
level to HIV-1 transmission risk, this analysis captures the
principal determinant of that risk. We are also in the process of
evaluating a per sexual contact model to address differences in
sexual frequency and condom use. Finally, our evaluation of HIV-
1 infections averted provides an approximate estimate derived by
extrapolation from the stable partnerships followed through the
clinical trial. More complex models are required to incorporate
population-level estimations with multiple risk groups having
different saturation levels and the impact of onward transmission.
Non-ART interventions, such as treatment of co-infections that
are associated with increased plasma HIV-1 levels, are currently
being evaluated to reduce HIV-1 infectiousness and disease
progression. If such interventions reduce plasma HIV-1 levels by
.0.7 log10 copies/mL, they may also provide a valuable tool for
prevention of HIV-1 transmission. HSV-2 suppression with
standard doses of acyclovir (as assessed in the Partners in
Prevention HSV/HIV Transmission Study) did not meet this
goal, and ongoing studies are evaluating whether higher doses of
herpes suppression are associated with a greater reduction in
plasma HIV-1 levels. Given the costs and challenges of trials
evaluating interventions to reduce HIV-1 transmission, there is a
need to prioritize which candidate interventions are evaluated.
This model of plasma HIV-1 RNA levels and HIV-1 transmission
risk provides a useful assessment tool for estimating the potential
HIV-1 prevention impact of reductions in plasma HIV-1 levels.
Supporting Information
Table S1
Found at: doi:10.1371/journal.pone.0012598.s001 (0.02 MB
XLS)
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